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SUMMARY.-Adrenocortical activity has been assessed in patients with
inoperable carcinoma of the bronchus or with disseminated malignant disease
ofother organs. The meanbasal plasma cortisol level was higher intheformer
than in the latter and both were higher than the controls. Each had abnormally
high midnight levels, particularly those with oat cell carcinoma ofthe bronchus.
After the administration of a single dose of dexamethasone both groups sup-
pressed poorly compared with the controls. Failure to suppress was associated
with a poor prognosis.
AN association between adrenocortical overactivity and a variety ofmalignant
tumours has been documented in recent years (Ross, 1969), and it is widely
believed that the high cortisol secretion rate is caused by production of poly-
peptide with adrenocorticotrophic activity- by the tumour itself rather than to
stimulation ofproduction and release ofpituitary corticotrophin by hypothalamic
overactivity resulting from the stress of dying or metastatic deposits within the
brain.
The present paper reports an investigation of the use of a dexamethasone
suppression test in an investigation ofpituitary-adrenal function in patients with
cancer, which throws doubt on this supposition; A'relationship between the
degree of suppression and prognosis has also been' demonstrated.
SUBJECTS
Eighty patients with a diagnosis of inoperable carcinoma of the bronchus
admitted for radiotherapy and/or cytotoxic drugs, but otherwise unselected, were
studied (Group 1) and compared with 45 patients with malignant disease of
organs other than the, lung (Group 2), which had metastasized'or were otherwise
considered unresectable. Both groups were studied before drug treatment or
radiotherapy was instituted and, in Group 2, at least 1 week after laparotomy
(when this was done). A control group of 35 patients (Group 3) was taken at
random from individuals'admitted for routine minor surgery. They were not
matched for sex or age with the cancer groups, nor had they pain, infections or
other obvious cause of stress apart from that of hospitalization. Subjects taking
oral contraceptives were excluded. Studies were not done on patients in Groups 1
and 2 within the first post-operative week.
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The patients in Groups 1 and 2 were divided into four clinical categories:
Stage I Without pain or breathlessness. Active and ambulant. Few
symptoms.
Stage II With pain or breathlessness. Restricted to bed for some part of the
day by weakness. No obvious signs ofgeneralized infection.
Stage III With severe pain or breathlessness. Bedridden.
Stage IV Terminal.
Deaths occurring within a month of the suppression test were recorded: those
due to causes unrelated to the malignant disease were excluded. In each group
some patients refused to take dexamethasone (see Table II).
TABLE I.-Plasma 1 1-hydroxycorticoid (1 I-OHCS) Concentration in Patients with
Carcinoma of the Bronchus and Other Organs (Means ± S.E.)
Cancer of the bronchus
Oat cell or
undiffer- Cancer of
Controls All types Squamous entiated other organs
9 a.mii.
Number 35 80 20 13 40
Plasma ll-OHCS .175±1-02 .23-9_0-88 267±2 06 2824-2 33 . 19-5±1-14
(yg./100 ml.)
Midnight
Number 35 . 52 19 13 30
Plasma ll-OHCS 9-6±1-02 . 1,53±108 16-9±2-25 2-3±3-2 16-6±1-44
(1g./100 ml.)
METHODS
Heparinized blood samples were taken from non-fasting patients at the
following times within a 24-hour period:
1. 8.30 a.m.-9.30 a.m. .. (basal level)
2. 11.00 p.m.-midnight .. (midnight level)
3. 8.30 a.m.-9.30 a.m. .. on the following day, after 2 mg. of dexa-
methasone had beengivenbymouthimmediately
after the collection of the midnight specimen
(post-suppression level).
Dexamethasone was given at midnight to anticipate and suppress the early-
morning rise in endogenous corticotrophin secretion.
Plasma 1 1-hydroxycorticoid concentration-assumed in this study to be a
measure of plasma cortisol concentration-was estimated by the fluorimetric
method of Mattingly (1962). Plasma potassium concentration was measured on
the 9.0 a.m. specimen in the patients of Groups 1 and 2 using a " Technicon"
Autoanalyser system.
RESULTS
The mean 9 a.m. plasma hydroxycorticoid concentration for 80 patients with
carcinoma ofthe bronchus of all cell types is shown in Table I, with the values for
individual cell types where known. Many of these patients were referred for
radiotherapy and a tissue diagnosis had not been obtained. All values in the
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FiG.. 1.-Basal and suppressed plasma cortisol levels for all cases in Group 1. Death occurring
within 1 month ofthe test is signified: - - -. In two patients X and Y the test was repeated.
These patients are referred to in the text.
cancer patients are significantly higher than in the controls with the exception of
basal levels for Group 2. Those with undifferentiated or oat cell carcinoma ofthe
bronchus had higher values than those with squamous cell carcinoma, and these
in turn were higher than those with cancer of other organs, but the differences
were not statistically significant. The reduction of diurnal variation in cancer
patients is also demonstrated (Table I). The midnight values of the two neo-
plastic groups were not significantly different and both were raised above the
control values (Table II). The midnight values for hospitalized patients had been
TABLE II.-Fasting Plasma 11-hydroxycorticoid Concentration and Per Cent
Suppression with Dexamethasone in Patients in Groups 1, 2 and 3
Plasma 11-hydroxycorticoid concentration (,ug./100 ml.)
(3) = (1-2) Percent
(2) Basal minus suppression
No. of (1) Post- post- (3) x 100
cases* Basal Midnight suppression suppression (1)x
Group 1 . Carcinoma 52 . 22-9±I1-t . 15-3±1-08 . 11-6±1-24 . 11-3 . 49
ofthe
bronchus
Group 2 . Carcinoma 40 . 19-5± 1-14 . 16-6± 1*44 . 10-7± 1-41 . 88 . 45
various
organs
Group 3 . Controls . 35 . 17-5±1-02 9-6±1-02 5-1±1-6 . 12-4 . 73
* Patients who completed the suppression test.
t Mean i S.E.M.
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FIG. 2.-Basal and suppressed plasma cortisol levels for all cases in Group 2. Death occurring
within 1 month of the test is signified: -- -. Patients A and B are referred to in the text.
found in previous studies (unpublished) to be considerably higher than those
found in non-hospitalized normal subjects (mean 4 5 ,ug./100 ml.). Both Groups
1 and 2 showed considerably less suppression than the control group (Table II,
Fig. 1, 2 and 3) and resistance to suppression was most prominent in the relatively
small group of patients having oat cell cancer of the bronchus.
It may be seen from Tables III and IV that with increasing physical disability
there was increasing resistance to suppression, but the number ofpatients in each
group is small. Table IV shows the relation of basal and post-suppression levels
to prognosis. The upper limit of normal for the 9 a.m. basal cortisol value has
TABLE III.-The Relation Between Clinical State, Basal Plasma I1-hydroxycorticoid
Concentration and Per Cent Suppression with Dexamethasone, in Patients of Group 2
Numbers
6
12
17
5
Plasma 11-hydroxycorticoid concentration (,ug./100 ml.)
(3)
(1) (2) Basal minus
Basal Post-suppression post-suppression
(Mean ± S.E.M.) (Mean ± S.E.M.) (1) -(2)
14-2 (±1-29) . 3-8 (±O- 34) . 10-4
15- 7 (±1- 96) . 7- 9 (±1-36) . 7- 8
22-0 (±1-46)* . 11-4 (±2-03) . 10-6
30-6 (±3 67)* . 19-5 (±8-47) . 11 1
Per cent
suppression
(3) x 100
(1)
73
50
48
36-3
* This figure is significantly different (P < 0 025) from the corresponding figure in the preceding
stage.
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FIG. 3.- Basal and suppressed plasma cortisol levels for all cases in Group 3.
TABLE IV.-Relation Between Clinical State, Fasting Plasma 11-hydroxycorticoid
Concentration, and Per Cent Suppression with Dexamethasone
Plasma li-hydroxycorticoid concentration(,ug./1OO ml.)
(3) Per cent
(1) (2) Basal minus suppression
Basal Post-suppression post-suppression (3) x 100
Stage Numbers (Mean ± S.E.M.) (Mean ± S.E.M.) (1) -(2) (1)
I 13 18-4 (41-33) . 5-3 (I1-81) 13-1 . 70-2
II 15 . 22-3 (±1.20) * 8-8 (±2-01) 13-5 60*5
III . 19 . 26-1 (±1-67) 15-7 (±1-95)* . 10-4 . 39-8
IV 5 . 31-7 (±2 53) . 28-4 (±2.23)* . 3.3 . 11 0
* This figure is significantly different (P < 0-025) from the corresponding figure in the preceding
stage.
been put at 26 ,ug./100 ml. The suppressed level of 11 ,tg./100 ml. has been
chosen as an arbitrary upper limit, having no biological significance.
Plasma potassium concentration was normal apart from 4 patients in Group 1
(2.0, 2.1, 3-2, 3.3 mEq/L) and 1 patient in Group 2 with advanced carcinoma ofthe
rectum (2.5 mEq/L). Hypokalaemia in these patients was not due to diarrhoea
or to diuretic therapy. Only one of the hypokalaemic patients in each group
had an elevated basal plasma cortisol concentration; furthermore, 2 of the hypo-
kalaemic subjects (in Group 1) suppressed adequately.
DISCUSSION
The short dexamethasone suppression test used employed a simple fluorimetric
method for determination of plasma steroid levels at 9 a.m. on two consecutive
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days, before and after the administration of a single dose of dexamethasone.
The standard suppression tests rely on timed urine collections and 6-hourly
administrations of dexamethasone which are difficult to perform accurately in
these sick patients and it is unlikely that they would have provided any more
qualitatively valuable information. If the corticotrophin concerned with the
adrenal overactivity found in cancer patients originated from the tumour, it is
improbable that the administration of dexamethasone would suppress its release.
The present results agree with the published findings of Werk, Sholiton and
Marnell (1963) and Lichter and Sirett (1968) of higher basal plasma li-hydroxy-
corticosteroid concentration in carcinoma of the bronchus than in non-cancerous
controls, but the basal level was not significantly higher in those with bronchogenic
than in those with nonbronchogenic neoplasms and those with oat cell cancer of
the bronchus did not differ from those with squamous cell type. Diurnal variation
was present but was less prominent in those with oat cell than in those with
squamous carcinoma of the bronchus. Groups 1 and 2 both showed a wide range
of suppressibility which included patients who suppressed to well below 11 jug.
and those with relatively poor suppression, which suggested that the feedback
mechanism was being overridden. In some instances, no suppression at all
occurred or a paradoxical increase was noted.
Excessive response to exogenous corticotrophin has been noted as a sign of
poor prognosis in carcinoma of the bronchus (Belsky and Marks, 1962; Hymes
andDoe, 1962), perhapsbecausehigh circulating cortisol levelsaccelerate thespread
of metastases (Iversen and Hj0rt, 1958). Previous studies have shown that such
a response provides a better index of prognosis than degree of clinical disability.
We have used a less elaborate but probably no more arbitrary classification of
clinical staging, and the results show a tendency for the mean basal cortisol levels
to increase and the degree of suppression to decrease with deterioration in clinical
condition. In 4 cases, the tests were of greater predictive value than the clinical
state, so that the test results were inconsistent with those of other cases staged
equally. For example, two of the patients (X, Y in Fig. 1) had carcinoma of the
bronchus; one was admitted for cervical node biopsy and the other for investiga-
tion of intermittent chest pain. Suppression tests were done on admission and
repeated just before death. Their results are shown in Fig. 1. The basal levels
were 285 and 284 ,g./100 ml., and post-suppression, 11.1 and 126 MLg.!100 ml.
respectively. Clinically, when first seen, they were well enough to be placed in
Stage I, but, to our surprise, had relatively high basal and suppressed levels.
They both rapidly deteriorated and developed superior vena cava obstruction
which did not respond to radiotherapy. Their suppression tests became even
more abnormal (basal levels, 30.1 and 33-4 ,ug./100ml. and post-suppression,
27-8 and 33.7 ,g./100 ml. respectively), and they died within a month.
The other two patients (A, B, Fig. 2) were both shown at laparotomy to have
inoperable carcinoma of the stomach. One was put in Stage II and his test
results were: Basal, 300 Mg./100 ml.; post-suppression, 255 Mg.!100 ml.: he
deteriorated very quickly and died within a month. The other patient was
clinically more ill initially and was placed in Stage IIIbecause ofsevere abdominal
pain and weakness. Although his basal level was high (36.5 Mug./100 ml.) he
suppressed to 7 0 ,g./100ml., suggesting on the basis of previous observations
that he was not terminal. In fact, he showed some clinical improvement after
laparotomyalthoughnotumourtissuewasremovedand hewasalive 2 monthslater.
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From these instances, and from Table IV, it may be seen that a high basal
plasma 11-hydroxycorticoid concentration reinforced by poor suppression after
the one-dose dexamethasone test suggests a poor prognosis. If the basal (9 a.m.)
plasma 11-hydroxycorticosteroid concentration in a patient with cancer exceeds
26 ,ug./100 ml. and after suppression with 2 mg. dexamethasone still exceeds
11 [g./100 ml., the probability that the patient will be dead within 4 weeks is
60 per cent. Failure to suppress with dexamethasone appears to be the sinister
aspect of adrenocortical overactivity as the percentage of patients with a post-
suppression plasma 1l-hydroxycorticoid concentration greater than 11 ,ug.1 00 ml.
who were dead within 1 month was 65 per cent in those with carcinoma of the
bronchus (all types) and 55 per cent in those with carcinoma of other organs.
These observations are complementary to those showing a correlation between
responsiveness to corticotrophin and survival time (Werk, Sholiton and Marnell,
1963).
These studies provide no direct answer to the question as to why overactivity
ofthe hypothalamic-pituitary-adrenal system should increase immediately before
death. Itis tempting to relate it to the stress of having a malignant disease and
either knowing or suspecting and fearing it. It does not appear to be related to
the physical state of the patient since some appeared well when admitted and
investigated, yet nevertheless quickly deteriorated and died.
The present study has emphasized the difficulty of making a positive diagnosis
of so-called " ectopic ACTH secreting tumours ", since many types of neoplasms
seem to behave according to a similar pattern and there is nothing qualitatively
unique about the adrenal function in oat cell carcinoma of the bronchus when
compared with other cell types and neoplasms of other tissues, although quanti-
tatively it outstrips the others. Some of these patients studied in this series may
have had the " ectopic ACTH " syndrome, but they were selected so that none
suffered from hypokalaemic alkalosis. Survival and response to treatment in a
large proportion of total cases seems to be related more to the ability to suppress
with a single dose of dexamethasone than to the clinical assessment. Measure-
ment of plasma l11-hydroxycorticoids may prove of value as a prognostic guide
in patients with cancer.
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